AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10986569 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged patients moved to highly supervised settings (professionally supervised group homes, supervised hostels, foster families).
Number of subjects: 192
Study 10986569 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged patients (20%) went to nursing homes due to loss of autonomy from physical disorders.
Number of subjects: 192
Study 10986569 — intervention group
Group type: COMPARATOR
Intervention: Inpatients remaining in the hospital.
Number of subjects: 192
Study 8636675 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a medical student
Number of subjects: 34
Study 8636675 — intervention group
Group type: COMPARATOR
Intervention: No medical student present
Number of subjects: 34
Study 1460195 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 43
Study 1460195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 6324586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (20 cc/kg weekly doses before and after transplantation)
Number of subjects: 36
Study 30357404 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive childhood-obesity intervention
Number of subjects: 929
Study 28792851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 17
Study 28792851 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 17
Study 25533447 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.75 mg on day 1)
Number of subjects: 24
Study 25533447 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg twice daily on days 1 through 5)
Number of subjects: 24
Study 25533447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiemetic therapy (5‐HT3 receptor antagonists, NK‐1RAs, and dexamethasone)
Number of subjects: 24
Study 25533447 — intervention group
Group type: COMPARATOR
Intervention: Consecutive‐day granisetron
Number of subjects: 24
Study 24146218 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with cetuximab
Number of subjects: 164
Study 24146218 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) without cetuximab
Number of subjects: 164
Study 20689518 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rEPO at 250 units kg(‐1) per dose, three times weekly for 6 weeks
Number of subjects: 119
Study 20689518 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous rEPO at 750 units kg(‐1) per dose, once weekly for 6 weeks
Number of subjects: 119
Study 19004650 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous hand cold stimulation
Number of subjects: 15
Study 19004650 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous foot cold stimulation
Number of subjects: 15
Study 19004650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic rectal electrical stimulation
Number of subjects: 15
Study 19004650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic rectal distension stimulation
Number of subjects: 15
Study 19004650 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotopic stimulation (hand and foot)
Number of subjects: 15
Study 16933087 — intervention group
Group type: EXPERIMENTAL
Intervention: High fidelity Integrated Dual Disorders Treatment program
Number of subjects: 182
Study 16933087 — intervention group
Group type: COMPARATOR
Intervention: Service as usual
Number of subjects: 182
Study 15245622 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0
Study 15245622 — intervention group
Group type: COMPARATOR
Intervention: Brokered Case Management (BCM)
Number of subjects: 0
Study 11359482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-implant connected prostheses
Number of subjects: 123
Study 11359482 — intervention group
Group type: COMPARATOR
Intervention: Freestanding implant-supported prostheses
Number of subjects: 123
Study 11359482 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid tooth-implant connected prostheses
Number of subjects: 123
Study 9413883 — intervention group
Group type: EXPERIMENTAL
Intervention: Short allele of the serotonin transporter gene
Number of subjects: 66
Study 9413883 — intervention group
Group type: COMPARATOR
Intervention: Control group (150 individuals)
Number of subjects: 66
Study 8481748 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated products
Number of subjects: 26
Study 8481748 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated products
Number of subjects: 26
Study 3436154 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam (400 mg single dose)
Number of subjects: 19
Study 3436154 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam (repeated dosing)
Number of subjects: 19
Study 3436154 — intervention group
Group type: COMPARATOR
Intervention: Isoxicam (compared to younger healthy population)
Number of subjects: 19
Study 31065236 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 60
Study 31065236 — intervention group
Group type: COMPARATOR
Intervention: Upper- and lower-cycle (ULC)
Number of subjects: 60
Study 29029101 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (0.056 mg/kg/d for a median duration of 6.5 years)
Number of subjects: 58
Study 25234274 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer assessment (PA)
Number of subjects: 149
Study 25234274 — intervention group
Group type: COMPARATOR
Intervention: Usual case discussion (CD)
Number of subjects: 149
Study 22554679 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg 3 times daily
Number of subjects: 0
Study 22554679 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg 3 times daily
Number of subjects: 0
Study 22554679 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 21733727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 7.5 mg/kg every 8 h (MDD)
Number of subjects: 100
Study 21733727 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 22.5 mg/kg as a single dose (ODD)
Number of subjects: 100
Study 19808139 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogeneric abciximab
Number of subjects: 37
Study 19808139 — intervention group
Group type: COMPARATOR
Intervention: Branded abciximab
Number of subjects: 37
Study 16786822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for anxiety
Number of subjects: 36
Study 16786822 — intervention group
Group type: COMPARATOR
Intervention: Children with comorbid anxiety and asthma
Number of subjects: 36
Study 15297066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix plus 1mg CPG 7909
Number of subjects: 60
Study 15297066 — intervention group
Group type: COMPARATOR
Intervention: Fluarix plus saline control
Number of subjects: 60
Study 15297066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix (1/10th dose)
Number of subjects: 60
Study 15297066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix (full dose)
Number of subjects: 60
Study 15297066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluarix plus 1mg CPG 7909 (in individuals with pre-existing immunity)
Number of subjects: 60
Study 12126992 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal condition
Number of subjects: 0
Study 12126992 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate arousal condition
Number of subjects: 0
Study 12126992 — intervention group
Group type: EXPERIMENTAL
Intervention: Low arousal condition
Number of subjects: 0
Study 12126992 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately novel foods
Number of subjects: 0
Study 12126992 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely novel foods
Number of subjects: 0
Study 9579717 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily for 8-10 days
Number of subjects: 60
Study 9579717 — intervention group
Group type: COMPARATOR
Intervention: Cefixime 400 mg once daily for 8-10 days
Number of subjects: 60
Study 9579717 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 60
Study 9579717 — intervention group
Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 60
Study 9579717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 7900711 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (as an adjunct to metoclopramide, dexamethasone, and clemastine)
Number of subjects: 180
Study 2767201 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence eye movements with a 20 ms vertical displacement pulse (up to 0.5 degrees)
Number of subjects: 3
Study 264440 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelium-containing graft from the hard palate
Number of subjects: 0
Study 264440 — intervention group
Group type: COMPARATOR
Intervention: Epithelium-free graft from the hard palate
Number of subjects: 0
Study 31590069 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-foot exercise (3 times per week for 8 weeks)
Number of subjects: 20
Study 31590069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 30020450 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models for training in flexible bronchoscopy (Model 2)
Number of subjects: 10
Study 27500949 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled syringe (PFS)
Number of subjects: 204
Study 27500949 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector
Number of subjects: 204
Study 27500949 — intervention group
Group type: COMPARATOR
Intervention: Comparison of autoinjector to PFS
Number of subjects: 204
Study 26299217 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle program for smoking cessation (Luchtsignaal(®))
Number of subjects: 800
Study 26299217 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle program for weight loss (Weight Watchers(®))
Number of subjects: 800
Study 26299217 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle program for improving physical activity (Philips DirectLife(®))
Number of subjects: 800
Study 26299217 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study 24793528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg conbercept (PRN)
Number of subjects: 122
Study 24793528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg conbercept (Q1M)
Number of subjects: 122
Study 24793528 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg conbercept (PRN)
Number of subjects: 122
Study 24793528 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg conbercept (Q1M)
Number of subjects: 122
Study 24793528 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg conbercept
Number of subjects: 122
Study 24793528 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mg conbercept
Number of subjects: 122
Study 22573504 — intervention group
Group type: EXPERIMENTAL
Intervention: REHACOP
Number of subjects: 76
Study 22573504 — intervention group
Group type: COMPARATOR
Intervention: Control (occupational therapy)
Number of subjects: 76
Study 19304712 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kV and 330 mAs
Number of subjects: 100
Study 19304712 — intervention group
Group type: COMPARATOR
Intervention: 120 kV and 330 mAs
Number of subjects: 100
Study 17332788 — intervention group
Group type: COMPARATOR
Intervention: Insulin stimulation alone
Number of subjects: 4
Study 17332788 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation with superimposed exercise
Number of subjects: 4
Study 17332788 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced glucose uptake
Number of subjects: 4
Study 15447902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-phosphate iron mineral ferritin
Number of subjects: 30
Study 15447902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-phosphate iron mineral ferritin
Number of subjects: 30
Study 15447902 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 30
Study 11251695 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (2400 mg/day)
Number of subjects: 143
Study 11251695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 9672272 — intervention group
Group type: COMPARATOR
Intervention: Stenting plus placebo
Number of subjects: 2399
Study 9672272 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 2399
Study 9672272 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus abciximab
Number of subjects: 2399
Study 9672272 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding complications
Number of subjects: 2399
Study 8021054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg
Number of subjects: 8
Study 8021054 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 8
Study 8021054 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 8
Study 8021054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31216584 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29778481 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-10 egg yolk antibodies (MAB, n = 71)
Number of subjects: 133
Study 29778481 — intervention group
Group type: COMPARATOR
Intervention: Control group without anti-IL-10 antibodies (MEP, n = 62)
Number of subjects: 133
Study 29778481 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-10 egg yolk antibodies (MAB)
Number of subjects: 133
Study 27448478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep for Success program (SFS)
Number of subjects: 71
Study 27448478 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 24532651 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based management of under-5 fever
Number of subjects: 520
Study 24532651 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age groups (15-25 years)
Number of subjects: 520
Study 24532651 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 26-45 years
Number of subjects: 520
Study 24532651 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group ≥46 years
Number of subjects: 520
Study 24532651 — intervention group
Group type: EXPERIMENTAL
Intervention: Community approval of CHWs
Number of subjects: 520
Study 24532651 — intervention group
Group type: EXPERIMENTAL
Intervention: Approval by CHW's immediate family
Number of subjects: 520
Study 21983163 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 10mg rosuvastatin
Number of subjects: 37
Study 21983163 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day dosing of 10mg rosuvastatin
Number of subjects: 37
Study 21250575 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz fiber posts (Endo Light post) cemented using dual cured resin cement (Prime & Bond NT + Fluorocore 2) with post space depth of 5 mm
Number of subjects: 30
Study 21250575 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz fiber posts (Endo Light post) cemented using dual cured resin cement (Prime & Bond NT + Fluorocore 2) with post space depth of 7 mm
Number of subjects: 30
Study 21250575 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz fiber posts (Endo Light post) cemented using dual cured resin cement (Prime & Bond NT + Fluorocore 2) with post space depth of 9 mm
Number of subjects: 30
Study 18445991 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS group (losartan 25 mg alone)
Number of subjects: 0
Study 18445991 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS+BUC group (losartan 25 mg after bucolome 300 mg for 7 days)
Number of subjects: 0
Study 18445991 — intervention group
Group type: COMPARATOR
Intervention: Group A (losartan 10 mg/kg for 14 days)
Number of subjects: 0
Study 18445991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (losartan 10 mg/kg and bucolome 50 mg/kg for 14 days)
Number of subjects: 0
Study 16330675 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-cisplatin (AP) chemotherapy (60 mg/m2 doxorubicin and 50 mg/m2 cisplatin every 3 weeks for seven cycles, followed by one cycle of cisplatin)
Number of subjects: 422
Study 16330675 — intervention group
Group type: COMPARATOR
Intervention: Whole-abdominal irradiation (WAI) (30 Gy in 20 fractions, with a 15-Gy boost)
Number of subjects: 422
Study 16330675 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-cisplatin (AP) chemotherapy
Number of subjects: 422
Study 16330675 — intervention group
Group type: COMPARATOR
Intervention: Whole-abdominal irradiation (WAI)
Number of subjects: 422
Study 14616410 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole + Warfarin
Number of subjects: 0
Study 14616410 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Warfarin
Number of subjects: 0
Study 11015972 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate referral for colposcopy at enrollment
Number of subjects: 5020
Study 11015972 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up with cytology only
Number of subjects: 5020
Study 11015972 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of HPV DNA testing to triage to colposcopy
Number of subjects: 5020
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic approach F.A. Gotch
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to E.G. Lowrei
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to R.M. Hakim
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to K.K. Jindal
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to P. Calzavara
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to J.T. Daugirdas
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to C. Basile
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to P. Malchesky
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to L. Garred et. al.
Number of subjects: 120
Study 8928327 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation according to approaches 2, 8 and 9
Number of subjects: 120
Study 1623493 — intervention group
Group type: EXPERIMENTAL
Intervention: NGLDM method
Number of subjects: 1290
Study 1623493 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular symmetric autoregressive random field model
Number of subjects: 1290
Study 1623493 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-variance method
Number of subjects: 1290
Study 6144829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal HDCV (0.1 ml doses)
Number of subjects: 94
Study 6144829 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular HDCV (1.0 ml doses)
Number of subjects: 94
Study 30086057 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation
Number of subjects: 40
Study 30086057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27216112 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy (dCBT) delivered via web and/or mobile channels
Number of subjects: 1000
Study 27216112 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE) comprising a website plus a downloadable booklet
Number of subjects: 1000
Study 27216112 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy (dCBT)
Number of subjects: 1000
Study 27216112 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 1000
Study 25244260 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous exercise training (60‐79% of max heart rate), 45-60 min, 3 times/week for 8 weeks
Number of subjects: 30
Study 25244260 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (antiretroviral therapy and counseling only)
Number of subjects: 30
Study 23013802 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg intravenously every 6 hours for 7 days) and Clonidine (0.1 mg per tube every 12 hours for 7 days)
Number of subjects: 0
Study 23013802 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Clonidine
Number of subjects: 0
Study 23013802 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 0
Study 20006165 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 10 mg
Number of subjects: 60
Study 20006165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18835099 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic phosphate buffer (pH 5.2) at 40 ml/h
Number of subjects: 72
Study 18835099 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic phosphate buffer (pH 5.2) at 20 ml/h
Number of subjects: 72
Study 18835099 — intervention group
Group type: COMPARATOR
Intervention: Normal phosphate buffer (pH 7.3) at 40 ml/h
Number of subjects: 72
Study 18835099 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline at 40 ml/h
Number of subjects: 72
Study 18835099 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic phosphate buffer (pH 5.2)
Number of subjects: 72
Study 16438016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium Bolus (0.15 mg/kg) - Group A
Number of subjects: 38
Study 16438016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium Infusion (0.18 mg/kg/h) - Group B
Number of subjects: 38
Study 12885803 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - two injections (group B)
Number of subjects: 64
Study 12885803 — intervention group
Group type: COMPARATOR
Intervention: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - single injection (group A)
Number of subjects: 64
Study 10475142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of distigmine (14C-distigmine-bromide)
Number of subjects: 0
Study 10475142 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 14C-distigmine-bromide
Number of subjects: 0